In recent years, treatment of CLL has moved away from traditional chemoimmunotherapy, which combined bendamustine plus rituximab (BR) or a more intense combination of fludarabine, cyclophosphamide and rituximab (FCR), or other variations incorporating a newer generation of CD20 monoclonal antibodies such as obinutuzumab or ofatumumab, to therapies targeting the Bruton tyrosine kinase (BTK) or B-cell Lymphoma 2 (BCL-2).2,3. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.